NCT01059175

Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial

Dual-Site LV Pacing in CRT Non Responders Multicenter Randomized V3 Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Medtronic Cardiac Rhythm and Heart Failure · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cardiac resynchronization therapy (CRT) is an effective treatment of heart failure (HF) refractory to optimal medical management, in presence of a depressed left ventricular (LV) ejection fraction and a wide QRS complex. It is mainly limited by a high proportion of non-responders. Attempts have been made, in small studies, to increase the number of stimulation sites in order to optimize the resynchronization therapy. V3 is a planned multicenter, randomized trial whose objective is to evaluate the clinical benefit conferred by the addition of a second endocardial or epicardial LV lead in non-responders after at least 6 months of standard biventricular stimulation. The V3 trial will examine the clinical benefit conferred by the addition of a second LV lead in non-responders compared to standard CRT.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DEVICE	Additional Endocardial or Epicardial LV Lead	Addition of a second left ventricular endocardial or epicardial lead
DEVICE	CRT-P or CRT-D	Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device

Timeline

• Start date: 2010-09-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2010-01-29
• Last updated: 2025-07-02
• Results posted: 2017-04-21

Locations

1 site across 1 country: France